Elevated serum calcium concentrations or the administration of exogenous calcimimetic agents can suppress calcium absorption via TRPV6 by activating the calcium-sensing receptor (CaSR) in intestinal epithelial cells, thus mitigating the onset of hypercalcemia (Lee et al., 2019; Hou et al., 2022). Here, CASR is linked to hypercalcemia disease.